The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Zhou, Fei ^a   Gao, Guanghui ^a   Ren, Shengxiang ^a   Li, Xuefei ^a   He, Yayi ^a   Zhou, Caicun ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOOXYGENASE 2; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER STAGING; CARDIOTOXICITY; CONTROLLED STUDY; COX 2 GENE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR GENE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE 2; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PLATINUM; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 84876422666     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061585     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98.
4. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-51.
5. Rabik CA, Dolan ME, (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23.
6. Gu S, Wu Q, Zhao X, Wu W, Gao Z, et al. (2012) Association of CASP3 polymorphism with hematologic toxicity in patients with advanced non-small-cell lung carcinoma treated with platinum-based chemotherapy. Cancer Sci 103: 1451-9.
7. Boulikas T, Pantos A, Bellis E, Petros C, (2007) Designing platinum compounds in cancer: structures and mechanisms. Cancer Therapy 5: 537-583.
8. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, et al. (1999) Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59: 198-204.
9. Setia S, Vaish V, Sanyal SN, (2012) Chemopreventive effects of NSAIDs as inhibitors of cyclooxygenase-2 and inducers of apoptosis in experimental lung carcinogenesis. Mol Cell Biochem 366: 89-99.
10. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA, (2002) Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 62: 6323-8.
11. Cory S, Adams JM, (2002) The Bcl2 family: regulators of the cellular life or death switch. Nat Rev Cancer 2: 647-56.
12. Ochiai M, Oguri T, Isobe T, Ishioka S, Yamakido M, (1999) Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn J Cancer Res 90: 1338-43.
13. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, et al. (1998) Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58: 4997-5001.
14. Zhang X, Miao X, Tan W, Ning B, Liu Z, et al. (2005) Identification of functional genetic variants in cyclooxygenase-2 and their association with risk esophageal cancer. Gastroenterology 129: 565-576.
15. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, et al. (2001) Cyclooxygenase-2 over expression is a marker of poor prognosis in stage I non-small cell cancer. Clin Cancer Res 7: 861-7.
16. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ, (2000) Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. J Biol Chem 275: 14838-14845.
17. Yang HJ, Youn H, Seong KM, Yun YJ, Kim W, et al. (2011) Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation. Biochem Pharmacol 82: 524-534.
18. Kim SH, Park HS, (2006) Genetic markers for differentiating aspirin-hypersensitivity. Yonsei Med J 47: 15-21.
19. Zhao D, Xu D, Zhang X, Wang L, Tan W, et al. (2009) Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology 136: 1659-68.
20. Bi N, Yang M, Zhang L, Chen X, Ji W, et al. (2010) Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Clin Cancer Res 16: 2383-90.
21. Hoff JH, te Morsche RH, Roelofs HM, van der Logt EM, Nagengast FM, et al. (2009) COX-2 polymorphisms -765G→C and -1195A→G and colorectal cancer risk. World J Gastroenterology 15: 4561-4565.
22. Iglesias D, Nejda N, Azcoita MM, Schwartz S Jr, González-Aguilera JJ, et al. (2009) Effect of COX2 -765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer. Cancer Causes Control 20: 1421-1429.
23. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, et al. (2002) Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22: 1631-1636.
24. Zhang XM, Zhong R, Liu L, Wang Y, Yuan JX, et al. (2011) Smoking and COX-2 functional polymorphisms interact to increase the risk of gastric cardia adenocarcinoma in Chinese population. PLoS One 6: e21894.
25. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, et al. (2000) 2000 update of recommendations for the use of hemato-poietic colony-stimulating factors: Evidence-based,clinical practice guidelines. J Clin Oncol 18: 3558-3585.
26. Zhang L, Gao G, Li X, Ren S, Li A, et al. (2012) Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy. PLoS One 7: e48350.
27. Shi YY, He L, (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15: 97-8.
28. Li Z, Zhang Z, He Z, Tang W, Li T, et al. (2009) A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res 19: 519-23.
29. Sonis ST, O'Donnell KE, Popat R, Bragdon C, Phelan S, et al. (2004) The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 40: 170-176.
30. Keskek M, Gocmen E, Kilic M, Gencturk S, Can B, et al. (2006) Increased expression of cyclooxygenase-2 (COX-2) in radiation-induced small bowel Injury in rats. J Surg Res 135: 76-84.
31. Kishi K, Petersen S, Petersen C, Hunter N, Mason K, et al. (2000) Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 60: 1326-31.
32. Stone HB, Coleman CN, Anscher MS, McBride WH, (2003) Effects of radiation on normal tissue: consequences and mechanisms. The Lancet Oncology 4: 529-36.
33. Dixon DA, (2003) Regulation of COX-2 expression in human cancers. Prog Exp Tumor Res 37: 52-71.
34. Ramsay RG, Barton AL, Gonda TJ, (2003) Targeting c-MYB expression in human disease. Expert Opin Ther Targets 7: 235-248.
35. Soza-Ried C, Hess I, Netuschil N, Schorpp M, Boehm T, (2010) Essential role of c-myb in definitive hematopoiesis is evolutionarily conserved. Proc Natl Acad Sci U S A 107: 17304-8.
36. Greig KT, Carotta S, Nutt SL, (2008) Critical roles for c-Myb in hematopoietic progenitor cells. Semin Immunol 20: 247-56.
37. Vegiopoulos A, García P, Emambokus N, Frampton J, (2006) Coordination of erythropoiesis by the transcription factor c-Myb. Blood 107: 4703-10.
38. Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, et al. (2008) Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib+chemotherapy-Cancer and Leukemia Group B Trial 30203. J Clin Oncol 26: 848-855.
39. Groen HJM, Sietsma H, Vincent A, Hochstenbag MMH, van Putten JWG, et al. (2011) Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: The NVALT-4 study. J Clin Oncol 29: 4320-4326.
40. Coskunpinar E, Eraltan IY, Turna A, Agachan B, (2011) Cyclooxygenase-2 gene and lung carcinoma risk. Med Oncol 28: 1436-1440.